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Abstract
Background
Tumour suppressor genes when mutated in the germline cause various cancers, but they
can also be somatically mutated in sporadic tumours. We hypothesized that there may also
be cancer-related germline variants in the genes commonly mutated in sporadic well-differ-
entiated thyroid cancer (WDTC).
Methods
We performed a two-stage case-control association study with a total of 2214 cases and
2108 healthy controls from an Italian population. By genotyping 34 single nucleotide poly-
morphisms (SNPs), we covered a total of 59 missense SNPs and SNPs located in the 5’
and 3’ untranslated regions (UTRs) of 10 different genes.
Results
The Italian1 series showed a suggestive association for 8 SNPs, from which three were
replicated in the Italian2 series. The meta-analysis revealed a study-wide significant asso-
ciation for rs459552 (OR: 0.84, 95%CI: 0.75–0.94) and rs1800900 (OR: 1.15, 95%CI:
1.05–1.27), located in the APC and GNAS genes, respectively. The APC rs459552 is a
missense SNP, located in a conserved amino acid position, but without any functional con-
sequences. The GNAS rs1800900 is located at a conserved 5’UTR and according to the
experimental ENCODE data it may affect promoter and histone marks in different cell
types.
Conclusions
The results of this study yield new insights on WDTC, showing that inherited variants in the
APC and GNAS genes can play a role in the etiology of thyroid cancer. Further studies are
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necessary to better understand the role of the identified SNPs in the development of WDTC
and to functionally validate our in silico predictions.
Introduction
Thyroid cancer (TC) is a common endrocrine malignancy. The majority of all thyroid cancers
are well-differentiated (WDTC). Among them the most frequent subtype is papillary TC
(PTC), followed by follicular TC (FTC); they represent 80–84% and 6–10% of all thyroid carci-
nomas, respectively [1]. The incidence of TC in the world has been increasing in recent years
and it accounts for about 1% of all oncological diseases based on the 2012 GLOBOCAN data
[2]. Explanations for the increasing thyroid cancer incidence are controversial [3]. Some
experts suggest that the rise in the number of new cancers is due to the increased diagnostic
intensity; other experts believe that it is associated to lifestyle changes. Many individual and
environmental factors have been considered as risk factors for TC. Indeed, thyroid gland
seems to be an organ particularly vulnerable to ionizing radiation and the risk for TC in indi-
viduals exposed to radiation at young age persists throughout life [4,5]. Benign nodules/adeno-
mas and goiter seem to have an important role in the predisposition to TC [6], as well as an
inherited genetic susceptibility [7,8]. Common genetic variants in low-penetrance genes may
interact with each other and with the environment, regulating TC susceptibility [9,10].
Many association studies, both designed candidate gene and genome-wide approaches,
have been conducted to identify genetic variants affecting individual susceptibility to WDTC.
In particular pathways involving DNA repair (OGG1,XRCC1,XRCC2,XRCC3,ATM), cell-
cycle control (TP53), detoxification (CYP1A1,GSTs) and thyroid function (TG) have been
intensively studied. Some genetic variants of these genes have been shown to be TC suscepti-
bility factors in humans [11–13]. Genome wide association studies (GWASs) of WDTC have
reported associations with single nucleotide polymorphisms (SNPs) at 2q35 (DIRC3), 8p12
(NRG1), 9q22.33 (FOXE1) and 14q13.3 (NKX2-1). These genetic risk factors were first identi-
fied in Icelandic and European studies, then replicated and confirmed across different popula-
tions [14–23]. Moreover, new risk loci at 20q11.22-q12 (DHX35) and 14q24.3 (BATF) were
recently discovered in a GWAS conducted on an Italian population and followed by replica-
tion on three different cohorts (Italian, Polish, Spanish) [23]. Other seven loci showed evidence
of association with WDTC only among Italians [22,23].
This study aimed to identify novel SNPs involved in WDTC susceptibility, selected in genes
somatically mutated in the disease. These genetic variants were analyzed in a two-stage case-
control association study. After identification of the candidate genes/polymorphisms associ-
ated with the disease, further verification was done by analyzing the functional consequences
using in silico prediction tools.
Materials and methods
Study population
The first Italian case group consisted of 1523 WDTC patients (85% PTC, 11% FTC, 27.4%
males, median age 53 years), while the control group comprised 1610 healthy individuals
(66.9% males, median age 57 years). The SNPs which showed significant associations (p
<0.05) were replicated in a second Italian sample set, totaling 691 affected individuals (100%
PTC, 22.4% males, median age 47 years) and 498 controls (23.1% males, median age 53
years), Table A in S1 File. The patients were contacted during their routine follow-up by the
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Department of Endocrinology and Metabolism (University Hospital of Cisanello, Pisa). All
patients had a histologically or cytologically confirmed WDTC. The healthy controls were
blood donors (University Hospital A. Meyer, Florence) and workers (mainly physicians,
nurses and paramedical staff), of the same Hospital of Pisa, without known thyroid disease.
The study was authorized by the Pisa University Medical Ethics Committee (CEAVNO,
North-West Tuscany Ethical Committee). According to the Helsinki declaration, all individu-
als signed an informed consent to participate to the study and to allow genetic analyses on
their biological samples.
Gene and SNP selection
The gene selection was done using the browser COSMIC (http://cancer.sanger.ac.uk/cosmic).
Starting from the 20 top genes mutated in PTC, we considered those with a mutation fre-
quency higher than 5%, obtaining a total of 11 genes (APC, BRAF,CDH1, CDKN2A,CTNNB1,
EGFR, GNAS, IDH1, SMAD4, TP53, TSHR). We considered all gene transcripts, then selected
all missense variants and SNPs located in the 5´UTR and 3´UTR, with a global minor allele fre-
quency (MAF) >10% and MAF >5% in the Italian population. We applied a tagging SNP
approach and checked the linkage disequilibrium (LD) of those variants in the Hap Map
Project (http://hapmap.ncbi.nlm.nih.gov/) and in the 1000 Genomes Project (http://www.
1000genomes.org/). By selecting SNPs with a pair wise LD r2<0.8, we reduced the number of
SNPs to be genotyped to 34 (5´UTR: 6, 3´UTR: 22 and missense: 6), covering 59 SNPs located
in 10 different genes, Table B in S1 File. The BRAF gene was not further included in our analy-
sis since it did not present any variants fulfilling our selection criteria.
Genotyping
Genotyping was performed using allele specific PCR based TaqMan Assays (Life Technolo-
gies) and KASPar v4.0 Assays (Kbioscience). HOT FIREPol Probe qPCR Mix Plus (ROX)
from Solis BioDyne (Tartu, Estonia) was used for the TaqMan Assays, whereas the KASPar
genotyping reaction from LGC was prepared according to the KBioscience’s conditions and
products (KASP Assay mix, containing the target specific primers, and KASP Master mix).
PCR reactions were performed in a 384-well plate format using 5ng DNA in a total reaction
volume of 5μl per well. Endpoint genotyping detection was performed using ViiA7 Real-Time
PCR System (Applied Biosystems, Weiterstadt, Germany).
Statistical analysis
The genotype distribution in controls was tested for Hardy-Weinberg equilibrium (HWE)
using the chi square (χ2) test. SNPs with a significant deviation from HWE (p<0.005) were
excluded from the analysis. Odd ratios (ORs) and 95% confidence intervals (95% CIs) were
calculated by logistic regression and adjusted for the covariates age and sex (PROC LOGISTIC,
SAS Version 9.2; SAS Institute, Cary, NC). For all SNPs, ORs were calculated according to the
allelic model using the major allele as reference. For SNPs with allelic pValue <0.05, we also
evaluated the associations according to co-dominant and dominant model using the major
homozygote genotype as reference. The pValue <0.05 was considered statistically significant.
The power of the study was evaluated using the Quanto Version 1.2 (USC Biostats), assuming
a case-control ratio of 1:1 in phase1 and 1:0.7 in phase 2, a baseline risk of 0.001, MAF of 0.1–
0.5, OR of 1.0–1.5 according to a log-additive inheritance model and a significance level of
0.05 (2-sided in phase 1; 1-sided in phase 2), Table C in S1 File. Furthermore, the meta-analysis
of the two Italian sets was conducted. ORs and 95% CIs were calculated using both fixed-effect
(Mantel-Haenszel) and random-effect (DerSimonian Laird) models. The significance of
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overall OR was evaluated by the Z-test. Heterogeneity between studies was evaluated with a Q-
test. Heterogeneity was considered significant when p<0.05. In case of no significant heteroge-
neity, point estimates and 95% CI were assessed using the fixed-effect model; otherwise, ran-
dom effects model was employed. Bonferroni´s correction was used, taking into account the
number of SNPs involved in the meta-analysis, and the novel statistical significant threshold
was 6.25×10−3.
In silico analysis
For each SNP significantly associated with WDTC risk, we carried-out in silico analysis to
determine its predicted functional effect and to understand the molecular events controlling
the gene expression. We performed SIFT and PolyPhen predictions to determine the possible
effect of amino acid substitutions on protein function [24]. We used the HaploRegv4.1 soft-
ware (http://www.broadinstitute.org/mammals/haploreg/haploreg.php) to investigate the
influence of the SNPs on gene expression [25]. It uses LD and SNP information from the 1000
Genomes Project to map known genetic variants onto ENCODE, providing a potential mecha-
nism for a SNP influence. ENCODE is a database which visualizes the influence of SNPs based
on their effect on chromatin structure, histone modifications, sequence conservation across
mammals, regulatory protein binding sites and their effect on regulatory motifs and transcrip-
tion factor binding sites (TFBSs). This tool includes also an expanded library of expression
quantitative trait loci (eQTL) [26]. As a complementary analysis we used the tool RegulomeDB
(http://regulomedb.org/) to identify DNA features and regulatory elements that contain the
coordinate of the SNP.
Results
A case-control association study was conducted with patients with sporadic WDTC, mainly
PTC, and healthy controls from an Italian population. The two subtypes, papillary and follicu-
lar TC, were not analyzed separately due to the small number of FTC (11% of cases). Genotype
distribution of three SNPs (rs3864004 in CTNNB1; rs2227983 and rs10228436 in EGFR) in
controls deviated from HWE (p<0.005) and they were excluded from further analyses.
The associations according to the allelic model between the SNPs and WDTC are shown in
Table 1. The analysis adjusted for the covariates age and sex, revealed a protective role (pValue
<0.05) for 5 SNPs: rs459552 within the APC gene; rs884904 within EGFR; rs8022600 and
rs2268477 within TSHR; rs7229678 within the SMDA4 gene. An increased risk of WTDC
(pValue <0.05) was found for the rare allele carriers of rs7144481 within TSHR gene, and of
rs1800900 and rs7121 within the GNAS gene.
Regarding the associated SNPs (pValue <0.05), we also evaluated the genotype risks in the
co-dominant and dominant models. For rs1800900 within the GNAS gene, the association of
minor homozygote genotype in comparison to the major homozygote genotype was stronger
than the association according to the allelic model (pValue = 8.82 x 10−3 vs. pValue = 0.01). A
dominant model described the association of rs7144481 in TSHRwith WDTC better than the
allelic model (pValue = 0.01 vs. pValue = 0.04).
To validate these findings, we conducted a replication study of the 8 SNPs, statistical signifi-
cant at the 0.05 level, by genotyping an additional Italian set of 691 cases and 498 controls.
Only three SNPs showed ORs in the same direction and at the same level as in the first set
(rs459552, rs7144481 and rs1800900). The combined analysis of the two data sets identified
two promising variants associated with WDTC risk: rs459552 within APC, (OR = 0.84, 95CI%
= 0.75–0.94, pValue = 4.00x10-3, allelic model) and rs1800900 within GNAS, (OR = 1.15, 95CI
% = 1.05–1.27, pValue = 4.00x10-3, allelic model). All the results are shown in Tables 2 and 3.
Genetic variants in thyroid cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0174995 April 14, 2017 4 / 13
In summary, the joint analysis detected a decreased risk of WDTC for one SNP (rs459552) in
APC and a positive association for one SNP (rs1800900) within GNAS.
To explore if the SNPs identified as WDTC risk markers have potential regulatory func-
tions, in silico methods were used to predict the effect of amino acid substitutions on protein
function and to understand the molecular events controlling gene expression. The results
shown in Table 4 summarize all the information obtained by utilizing the HaploRegv4.1 soft-
ware and RegulomeDB. The GNAS gene SNP rs1800900 was identified by SiPhy to be located
in a conserved region. As reported by the ENCODE project data, rs1800900 may affect DNAse
Table 1. Association between genotyped SNPs and WDTC risk in the Italian set1. (*) SNPs with a p-ValueHWE <0.005 in controls were excluded from
further analyses.
Unadjusted Adjusted for sex and age
Gene SNP Minor allele Allelic OR 95% CI pValue Allelic OR 95% CI pValue
IDH1 rs12478635 (T) 0.98 [0.87–1.10] 0.68 0.94 [0.82–1.07] 0.33
CTNNB1* rs3864004 (A) 0.98 [0.89–1.09] 0.76 0.94 [0.84–1.06] 0.33
CTNNB1 rs2953 (G) 0.99 [0.90–1.10] 0.90 0.96 [0.85–1.08] 0.47
APC rs459552 (T) 0.88 [0.78–1.00] 0.05 0.84 [0.73–0.96] 0.01
APC rs41116 (C) 0.98 [0.89–1.09] 0.73 1.02 [0.91–1.15] 0.72
APC rs397768 (G) 0.96 [0.87–1.10] 0.45 0.91 [0.80–1.02] 0.10
EGFR* rs2227983 (A) 1.00 [0.90–1.12] 0.94 0.96 [0.85–1.09] 0.56
EGFR* rs10228436 (A) 1.03 [0.93–1.14] 0.61 0.98 [0.88–1.11] 0.79
EGFR rs884225 (C) 0.94 [0.80–1.10] 0.45 0.86 [0.71–1.04] 0.12
EGFR rs884904 (A) 0.89 [0.75–1.06] 0.20 0.82 [0.67–0.99] 0.04
EGFR rs2280653 (G) 1.17 [1.00–1.36] 0.05 1.19 [1.00–1.42] 0.05
EGFR rs940810 (T) 0.99 [0.89–1.10] 0.84 1.02 [0.90–1.16] 0.75
EGFR rs6593211 (A) 1.02 [0.90–1.15] 0.77 1.00 [0.87–1.14] 0.96
EGFR rs34462843 (C) 1.09 [0.96–1.24] 0.18 1.08 [0.93–1.26] 0.29
TSHR rs8022600 (T) 0.87 [0.78–0.96] 5.40×10−3 0.82 [0.73–0.92] 1.13×10−3
TSHR rs3783941 (C) 0.97 [0.87–1.09] 0.61 1.00 [0.88–1.14] 0.96
TSHR rs1991517 (G) 1.06 [0.88–1.28] 0.53 1.01 [0.81–1.25] 0.96
TSHR rs7144481 (C) 1.12 [0.97–1.31] 0.12 1.20 [1.01–1.43] 0.04
TSHR rs17630128 (C) 1.02 [0.91–1.14] 0.78 1.02 [0.89–1.16] 0.82
TSHR rs2288493 (T) 1.04 [0.91–1.18] 0.60 1.08 [0.92–1.26] 0.34
TSHR rs2288495 (C) 1.01 [0.91–1.12] 0.82 1.01 [0.90–1.14] 0.87
TSHR rs2268477 (A) 0.78 [0.66–0.92] 3.49×10−3 0.75 [0.62–0.91] 3.96×10−3
CDH1 rs1801026 (T) 1.11 [0.96–1.28] 0.16 1.08 [0.91–1.27] 0.37
CDKN2A rs3088440 (A) 0.99 [0.81–1.21] 0.92 0.97 [0.77–1.21] 0.76
CDKN2A rs11515 (C) 1.07 [0.93–1.22] 0.35 1.13 [0.96–1.32] 0.13
CDKN2A rs3731249 (T) 1.04 [0.82–1.33] 0.74 1.12 [0.85–1.48] 0.43
CDKN2A rs2518720 (T) 1.06 [0.95–1.17] 0.31 1.09 [0.96–1.23] 0.17
TP53 rs1042522 (G) 0.94 [0.84–1.06] 0.33 0.96 [0.84–1.09] 0.50
SMAD4 rs7229678 (C) 0.90 [0.81–1.00] 0.05 0.86 [0.76–0.97] 0.01
SMAD4 rs12456284 (G) 0.88 [0.79–0.99] 0.03 0.89 [0.78–1.01] 0.07
GNAS rs1800900 (A) 1.13 [1.02–1.25] 0.02 1.17 [1.04–1.31] 0.01
GNAS rs8125112 (C) 1.07 [0.92–1.25] 0.37 1.09 [0.91–1.29] 0.34
GNAS rs13831 (A) 1.01 [0.91–1.14] 0.79 1.03 [0.90–1.17] 0.66
GNAS rs7121 (C) 1.18 [1.07–1.32] 1.47×10−3 1.23 [1.09–1.39] 7.90×10−4
SNP: single nucleotide polymorphism, OR: odd ratio, CI: confidence interval
https://doi.org/10.1371/journal.pone.0174995.t001
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hypersensitivity sites and enhancer and promoter histone marks in different cell types. Several
other linked SNPs show similar functional characteristics. Moreover, Regulome analysis
revealed that according to the ChIP-seq data this SNP is involved in GATA1 protein binding
sites (data not shown).
The APC gene SNP rs459552 is causing a missense amino acid change (Val1822Asp) in
three Ensembl transcripts. However, in all three transcripts it seems to be tolerated by SIFT
and considered to be benign by PolyPhen prediction. According to HaploReg v4.1 predictions,
this variant alters the binding sites of Bbx and LRH1 transcription factors and it is located in a
conserved amino acid position.
Discussion
To identify new risk variants predisposing to WDTC we investigated genes somatically
mutated in the disease for inherited germline polymorphisms, and performed an association
study in two case-control sets from Italy. By genotyping of 34 SNPs, we got information of 53
missense SNPs and SNPs located in the 5’ and 3’UTRs of 10 different genes. The Italian1 series
showed a suggestive association for 8 SNPs and three of them provided evidence of association
in the replication set. Finally, the meta-analysis revealed a study-wide significant association
for rs459552 and rs1800900, in the APC and GNAS genes, respectively.
Although the origin of the samples was the same, there were some differences in the two
data sets. First, the Italian1 series was dominated by female cases, while men were the larger
group among controls. The Italian2 series was more homogeneous regarding the gender
Table 2. Association of the 8 top SNPs in the two Italian sets with WDTC risk (Part I).
Italian1* Italian2* Combined
Gene/SNP Case Control OR [95% CI] pValue Case Control OR [95% CI] pValue OR [95% CI] pValue
APC (rs459552) AA 903 908 1.0 [reference] 430 296 1.0 [reference]
AT 498 553 0.85[0.71–1.01] 0.07 214 172 0.93[0.71–1.20] 0.56 0.87[0.76–1.01] 0.07
TT 68 91 0.68[0.47–0.99] 0.04 26 28 0.57[0.32–1.03] 0.06 0.65[0.47–0.88] 6.00 × 10−3
AT + TT 566 644 0.83[0.70–0.99] 0.03 240 200 0.87[0.68–1.12] 0.28 0.84[0.73–0.97] 0.02
Per allele 0.84[0.73–0.96] 0.01 0.85[0.69–1.05] 0.13 0.84[0.75–0.94] 4.00 × 10−3
EGFR (rs884904) GG 1212 1238 1.0 [reference] 529 404 1.0 [reference]
AG 243 287 0.80[0.64–0.99] 0.04 127 87 1.12[0.82–1.53] 0.48 0.89[0.75–1.07] 0.22
AA 16 16 0.80[0.35–1.82] 0.60 7 3 2.22[0.56–8.80] 0.26 1.05[0.52–2.12] 0.90
AG + AA 259 303 0.80[0.65–0.98] 0.04 134 90 1.15[0.85–1.57] 0.36 0.90[0.75–1.06] 0.20
Per allele 0.82[0.67–0.99] 0.04 1.17[0.88–1.56] 0.27 0.92[0.78–1.08] 0.30
TSHR (rs8022600) GG 464 411 1.0 [reference] 186 167 1.0 [reference]
GT 693 744 0.79[0.65–0.95] 0.01 362 237 1.37[1.04–1.80] 0.02 1.03[0.60–1.77] 0.91
TT 313 363 0.68[0.54–0.86] 1.51 × 10−3 131 92 1.17[0.82–1.66] 0.40 0.88[0.52–1.50] 0.63
GT + TT 1006 1107 0.75[0.63–0.90] 2.44 × 10−3 493 392 1.32[1.02–1.71] 0.04 0.99[0.57–1.72] 0.96
Per allele 0.82[0.73–0.92] 1.13 × 10−3 1.12[0.94–1.33] 0.20 0.95[0.70–1.29] 0.75
TSHR (rs7144481) TT 1090 1189 1.0 [reference] 490 362 1.0 [reference]
CT 360 331 1.30[1.07–1.59] 9.17 × 10−3 187 123 1.08[0.82–1.42] 0.60 1.22[1.04–1.43] 0.01
CC 25 29 0.92[0.50–1.71] 0.80 14 11 0.97[0.42–2.22] 0.93 0.94[0.57–1.54] 0.80
CT + CC 385 360 1.27[1.05–1.54] 0.01 201 134 1.07[0.82–1.39] 0.63 1.20[1.02–1.40] 0.02
Per allele 1.20[1.01–1.43] 0.04 1.05[0.83–1.33] 0.69 1.14[0.99–1.32] 0.06
SNP: single nucleotide polymorphism, OR: odd ratio, CI: confidence interval
(*) The analysis was conducted adjusting for the covariates of sex and age
https://doi.org/10.1371/journal.pone.0174995.t002
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distribution, with a female dominance both among cases and controls. Also, both the cases and
controls were older in the first set than in the second one. However, there was no significant
difference in allele frequencies between women and men among cases or controls. To avoid
sampling biases the analysis was adjusted for age and sex, but the replication series did not have
enough statistical power to confirm all the statistically significant results of the first data set. In
the first phase, we had an over 80% power to detect an OR of 1.2 for variants with MAF > 20%,
however, in the second phase the power was reduced to 56% for variants with MAF of 20%,
increasing to 71% for variants with MAF of 50%. As most of the associations were on opposite
directions in the two sample sets, they could be considered as false positives in the first sample
set. However, the strength of the association of rs459552 (pValue = 4.00x10-3) and rs1800900
(pValue = 4.00x10-3), together with the in silico data suggests that these two associations may
be real.
Our gene selection was based on somatic TC mutation data available at the COSMIC
browser. Comparison with the TCGA data showed very similar mutation spectrum, with
BRAF being the most commonly mutated gene in PTC [27]. The mutation frequencies in gen-
eral were, however, usually lower than in COSMIC, also for the genes included in our study. In
the current data APC is reported to be mutated in 10% of PTC by COSMIC, but only in 0.7%
of PTC by TCGA. For GNAS, COSMIC reports a 3% mutation frequency, while in TCGA
GNAS is not included among the top 25 genes.
The Adenomatous Polyposis Coli (APC) gene encodes a tumor suppressor protein that acts
as an antagonist of the Wnt signaling pathway. It is also involved in other processes including
cell migration and adhesion, transcriptional activation, and apoptosis. Defects in this gene
Table 3. Association of the 8 top SNPs in the two Italian sets with WDTC risk (Part II).
Italian1* Italian2* Combined
Gene/SNP Case Control OR [95% CI] pValue Case Control OR [95% CI] pValue OR [95% CI] pValue
APC (rs459552) AA 903 908 1.0 [reference] 430 296 1.0 [reference]
AT 498 553 0.85[0.71–1.01] 0.07 214 172 0.93[0.71–1.20] 0.56 0.87[0.76–1.01] 0.07
TT 68 91 0.68[0.47–0.99] 0.04 26 28 0.57[0.32–1.03] 0.06 0.65[0.47–0.88] 6.00 × 10−3
AT + TT 566 644 0.83[0.70–0.99] 0.03 240 200 0.87[0.68–1.12] 0.28 0.84[0.73–0.97] 0.02
Per allele 0.84[0.73–0.96] 0.01 0.85[0.69–1.05] 0.13 0.84[0.75–0.94] 4.00 × 10−3
EGFR (rs884904) GG 1212 1238 1.0 [reference] 529 404 1.0 [reference]
AG 243 287 0.80[0.64–0.99] 0.04 127 87 1.12[0.82–1.53] 0.48 0.89[0.75–1.07] 0.22
AA 16 16 0.80[0.35–1.82] 0.60 7 3 2.22[0.56–8.80] 0.26 1.05[0.52–2.12] 0.90
AG + AA 259 303 0.80[0.65–0.98] 0.04 134 90 1.15[0.85–1.57] 0.36 0.90[0.75–1.06] 0.20
Per allele 0.82[0.67–0.99] 0.04 1.17[0.88–1.56] 0.27 0.92[0.78–1.08] 0.30
TSHR (rs8022600) GG 464 411 1.0 [reference] 186 167 1.0 [reference]
GT 693 744 0.79[0.65–0.95] 0.01 362 237 1.37[1.04–1.80] 0.02 1.03[0.60–1.77] 0.91
TT 313 363 0.68[0.54–0.86] 1.51 × 10−3 131 92 1.17[0.82–1.66] 0.40 0.88[0.52–1.50] 0.63
GT + TT 1006 1107 0.75[0.63–0.90] 2.44 × 10−3 493 392 1.32[1.02–1.71] 0.04 0.99[0.57–1.72] 0.96
Per allele 0.82[0.73–0.92] 1.13 × 10−3 1.12[0.94–1.33] 0.20 0.95[0.70–1.29] 0.75
TSHR (rs7144481) TT 1090 1189 1.0 [reference] 490 362 1.0 [reference]
CT 360 331 1.30[1.07–1.59] 9.17 × 10−3 187 123 1.08[0.82–1.42] 0.60 1.22[1.04–1.43] 0.01
CC 25 29 0.92[0.50–1.71] 0.80 14 11 0.97[0.42–2.22] 0.93 0.94[0.57–1.54] 0.80
CT + CC 385 360 1.27[1.05–1.54] 0.01 201 134 1.07[0.82–1.39] 0.63 1.20[1.02–1.40] 0.02
Per allele 1.20[1.01–1.43] 0.04 1.05[0.83–1.33] 0.69 1.14[0.99–1.32] 0.06
SNP: single nucleotide polymorphism, OR: odd ratio, CI: confidence interval
(*) The analysis was conducted adjusting for the covariates of sex and age
https://doi.org/10.1371/journal.pone.0174995.t003
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Table 4. In silico analysis of the predicted regulatory elements in the region surrounding the SNPs in high LD with the 2 most promising variants.
SNP LD
(r2)
GENCODE
genes
SiPhy
cons
Promoter histone
marks
Enhancer histone
marks
DNAse Proteins
bound
Motifs
changed
GRASP
QTL hits
Selected
eQTL hits
rs34999673 0.84 GNAS-AS1 IPSC, BRST, MUS,
BLD
ESC, ESDR,
BRN, ADRL, HRT,
MUS, GI
rs4812035 0.99 GNAS-AS1 MUS ESDR, ESC,
IPSC, ADRL,
HRT, MUS,
PLCNT, GI
Cdx, Foxa,
Foxd3, Foxf1,
Foxj1, Foxl1,
Foxp1, Hbp1,
Mef2, Ncx,
Pax4, Pou1f1,
Pou3f1,
Pou3f2,
Pou3f3, Sox
rs67008625 0.92 GNAS-AS1 IPSC, SPLN ESDR, ESC,
IPSC, SKIN, BRN,
MUS
rs3761263 1 GNAS-AS1 ESC, ESDR, IPSC,
BLD, GI, KID,
MUS, PLCNT,
LNG, PANC, HRT,
SPLN
ESC, ESDR,
IPSC, BRST,
BLD, SKIN, LIV,
BRN, ADRL,
PANC, LNG,
MUS, GI, THYM,
PLCNT, HRT,
SPLN, KID
ESC,
IPSC,
MUS
CEBPB, Sox
rs1800900 1 GNAS ✓ ESC, ESDR, LNG,
IPSC, FAT, STRM,
BRST, BLD, MUS,
BRN, SKIN, VAS,
LIV, GI, ADRL,
HRT, KID, PANC,
PLCNT, OVRY,
SPLN, CRVX,
BONE
ESC, ESDR,
LNG, IPSC, FAT,
STRM, BRST,
BLD, MUS, BRN,
SKIN, LIV, GI,
ADRL, PLCNT,
THYM, PANC,
HRT, SPLN, FAT
ESDR,
ESC,
IPSC,
BRST,
SKIN,
MUS,
PLCNT
1 hit
rs1800905 1 GNAS ESC, ESDR, IPSC,
STRM, BLD, SKIN,
BRN, GI, ADRL,
KID, PANC, MUS,
PLCNT, HRT,
SPLN, FAT, LNG
ESC, ESDR,
IPSC, BRST,
BLD, STRM,
BRN, SKIN, LIV,
GI, ADRL, LNG,
MUS, PLCNT,
THYM, PANC,
HRT, SPLN
ESDR,
IPSC,
SKIN, GI
SUZ12 E2A, Myf,
Pou2f2, RXRA,
TCF12
2 hits
rs3787497 0.99 GNAS ESC, ESDR, IPSC,
STRM, SKIN,
ADRL, KID, PANC,
MUS, PLCNT,
HRT, SPLN, BRN,
FAT, GI, LNG
ESC, ESDR,
IPSC, BLD, SKIN,
GI, ADRL, LNG,
MUS, PLCNT,
HRT, SPLN
ESC,
IPSC,
SKIN
SUZ12 BCL, Hic1, NF-
kappaB, Nkx2,
Roaz
rs6123832 1 GNAS ESC, ESDR, IPSC,
STRM, KID, PANC,
MUS, SPLN, BRN,
ADLR, HRT, LNG,
GI
ESC, ESDR,
IPSC, STRM,
SKIN, GI, KID,
MUS, PLCNT,
LNG
ESC,
ESDR,
IPSC
POL24H8 Ik-2 2 hits
rs6026557 0.91 GNAS ESC, ESDR, IPSC,
BLD
ESC, ESDR,
IPSC, STRM,
ADRL, PANC,
MUS, PLCNT
Rad21,TATA 1 hit
rs56335290 0.81 6.6kb 5’ of
APC
ADRL Arid3a, Pou2f2,
Pou3f2
(Continued )
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cause familial adenomatous polyposis (FAP), an autosomal dominant pre-malignant disease.
FAP is an inherited condition caused by germline mutations in the APC gene [28]. In addition,
somatic mutations of APC are observed in sporadic colorectal neoplasm, suggesting that dis-
ruption of this tumor suppressor gene may play a role in both familial as well as acquired
colorectal tumorigenesis [29]. APC has been found to be expressed in normal as well as in neo-
plastic human thyroid tissue, in which multiple forms of specific RNA transcripts have been
detected; it may be hypothesized that alterations in APC are likely candidates for a pathogenic
role in thyroid tumorigenesis [30]. A study of mutations in Beta-catenin and APC genes in
PTC, FTC and benign thyroid tumors suggested that mutations in these genes are rare and
that the activation of the Wnt signaling pathway may not contribute to pathogenesis in human
PTC and FTC [31]. However, a better insight into the correlation of APC gene mutations on
the clinical manifestation of PTC requires further investigation as suggested by a study, which
investigated gene variants associated with malignant thyroid disease in FAP. In this patient
group carrying an APC mutation the prevalence of thyroid malignant diseases was estimated
to be 3.7% [32].
In our study, the variant allele carriers of the APC SNP rs459552 had a 16% decreased risk
of WDTC. The SIFT and PolyPhen predictions did not reveal any damaging effect for this
SNP. The effects of APC rs459552 substitutions on colorectal cancer (CRC) risk has been
investigated but no association between the genetic variant and CRC risk in the Scottish popu-
lation was observed [33]. Instead, previous studies investigating the possible influence of
rs459552 on the association between dietary and lifestyle factors and CRC showed significant
results. Indeed, the polymorphism of APC gene may have functional significance, especially in
the presence of diet, life-style, or other environmental exposures [34]. In a group of Portuguese
subjects, a significant interaction was found between the rs459552 polymorphisms and dietary
intake of high fat, cholesterol, calcium, and fiber for CRC risk [35].
Our statistical analysis showed a strong association between rs1800900, located in the
GNAS gene, with WDTC. GNAS encodes the α-subunit of the Gs protein (Gsα), which binds
GTP and stimulates adenylyl cyclase [36]. Somatic mutations in Gsα, and in TSHR gene, are
the main reason for autonomously functioning, TSH-independent, thyroid nodules in iodine-
deficient regions of the world [37,38]. In Gsα, activating mutations result in constitutive acti-
vation of the cAMP cascade, which determines clonal expansion of the affected thyroid cells
and consequent thyroid autonomy [39]. Studies from Japan reported that somatic mutations
of the Gsα and TSHR genes were caused by point mutations with single amino acid substitu-
tions, which were confined to the hyperfunctioning nodule and which were not presented in
neighboring normal thyroid parenchyma [40–42]. No information about rs1800900 has been
reported in literature. This SNP seems to be involved in GATA1 protein binding. It has been
recognized that GATA1, binding erythroid enhancers of specific genes, acts as a transcrip-
tional activator and it is involved in the differentiation of hematopoietic stem cells to erythro-
cytes [43]. GATA1 collaborates with BRG1 to disrupt chromatin, regulating the reorganization
of nucleosomes at enhancer elements and the binding of transcription factors to those specific
DNA sequences [44].
Table 4. (Continued)
SNP LD
(r2)
GENCODE
genes
SiPhy
cons
Promoter histone
marks
Enhancer histone
marks
DNAse Proteins
bound
Motifs
changed
GRASP
QTL hits
Selected
eQTL hits
rs459552 1 APC ✓ BRN Bbx, LRH1 3 hits Whole_Blood
SNP: single nucleotide polymorphism, LD: linkare disequilibrium, eQTL: expression quantitative trait loci
https://doi.org/10.1371/journal.pone.0174995.t004
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In conclusion, our study provides evidence for the hypothesis that polymorphic variants in
the APC and GNAS genes, which are commonly mutated in sporadic TC, may play a role in
the etiology of TC. Further analysis and additional investigations are needed to confirm our
results and to validate the accuracy and the specificity of our in silico predictions.
Supporting information
S1 File. Table A. Characteristics of the study population. Table B. SNP selection. In bold
all the SNPs genotyped. SNPs with MAF<0.10 were excluded from the analysis as were the
SNPs with a bad sequence (). From SNPs in high LD (r2>0.80; ) only one SNP was geno-
typed. a) Assay not available. Instead a SNP in high LD (r2 = 0.99) was genotyped, rs2518720.
Table C. Statistical power of the TC association study according to Quanto 1.2 power cal-
culation tool. Based on our study data we used a case-control ratio of 1:1 in phase 1 and
1:0.7 in phase 2, a baseline risk of 0.001, risk allele frequency between 0.1 and 0.5, odds ratio
between 1.0 and 1.5, according to a log-additive inheritance model at a significance level of
0.05 (2-sided in phase 1; 1-sided in phase 2).
(DOCX)
Acknowledgments
We are grateful to the study participants and the study investigators and coordinators for work
in recruitment of subjects. The study has received financial support from the Istituto Toscano
Tumori. All authors had full access to all the data in the study and take responsibility for the
integrity of the data and the accuracy of the data analysis.
Author Contributions
Conceptualization: KH FG SL AF.
Data curation: KH FG SL AF.
Formal analysis: CC.
Funding acquisition: KH FG SL AF.
Investigation: CC AK GF.
Methodology: CC AF.
Project administration: CC AK GF KH AF MC.
Resources: CC RE CR FB KH AF.
Software: CC AK GF.
Supervision: AF.
Validation: CC AF.
Visualization: CC.
Writing – original draft: CC.
Writing – review & editing: CC AF.
Genetic variants in thyroid cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0174995 April 14, 2017 10 / 13
References
1. Paschke R, Lincke T, Muller SP, Kreissl MC, Dralle H, et al. (2015) The Treatment of Well-Differentiated
Thyroid Carcinoma. Dtsch Arztebl Int 112: 452–458. https://doi.org/10.3238/arztebl.2015.0452 PMID:
26205749
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, et al. (2015) Cancer incidence and mortality
worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359–386.
https://doi.org/10.1002/ijc.29210 PMID: 25220842
3. Morris LG, Sikora AG, Tosteson TD, Davies L (2013) The increasing incidence of thyroid cancer: the
influence of access to care. Thyroid 23: 885–891. https://doi.org/10.1089/thy.2013.0045 PMID:
23517343
4. Dilas LT, Bajkin I, Icin T, Paro JN, Zavisic BK (2012) [Iodine and thyroid gland with or without nuclear
catastrophe]. Med Pregl 65: 489–495. PMID: 23297615
5. Niazi AK, Niazi SK (2011) Endocrine effects of Fukushima: Radiation-induced endocrinopathy. Indian J
Endocrinol Metab 15: 91–95. https://doi.org/10.4103/2230-8210.81936 PMID: 21731864
6. Meinhold CL, Ron E, Schonfeld SJ, Alexander BH, Freedman DM, et al. (2010) Nonradiation risk factors
for thyroid cancer in the US Radiologic Technologists Study. Am J Epidemiol 171: 242–252. https://doi.
org/10.1093/aje/kwp354 PMID: 19951937
7. Hemminki K, Dong C (2001) Population-based study of familial medullary thyroid cancer. Fam Cancer
1: 45–49. PMID: 14574015
8. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R (2013) Worldwide increasing incidence of
thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013: 965212. https://doi.
org/10.1155/2013/965212 PMID: 23737785
9. Canzian F, Amati P, Harach HR, Kraimps JL, Lesueur F, et al. (1998) A gene predisposing to familial
thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 63: 1743–1748.
https://doi.org/10.1086/302164 PMID: 9837827
10. Sturgis EM, Li G (2009) Molecular epidemiology of papillary thyroid cancer: in search of common
genetic associations. Thyroid 19: 1031–1034. https://doi.org/10.1089/thy.2009.1597 PMID: 19803789
11. Garcia-Quispes WA, Perez-Machado G, Akdi A, Pastor S, Galofre P, et al. (2011) Association studies
of OGG1, XRCC1, XRCC2 and XRCC3 polymorphisms with differentiated thyroid cancer. Mutat Res
709–710: 67–72. https://doi.org/10.1016/j.mrfmmm.2011.03.003 PMID: 21414327
12. Landa I, Robledo M (2011) Association studies in thyroid cancer susceptibility: are we on the right
track? J Mol Endocrinol 47: R43–58.
13. Damiola F, Byrnes G, Moissonnier M, Pertesi M, Deltour I, et al. (2014) Contribution of ATM and
FOXE1 (TTF2) to risk of papillary thyroid carcinoma in Belarusian children exposed to radiation. Int J
Cancer 134: 1659–1668. https://doi.org/10.1002/ijc.28483 PMID: 24105688
14. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Sigurdsson A, et al. (2009) Common vari-
ants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet 41:
460–464. https://doi.org/10.1038/ng.339 PMID: 19198613
15. Matsuse M, Takahashi M, Mitsutake N, Nishihara E, Hirokawa M, et al. (2011) The FOXE1 and NKX2-1
loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population. J Med
Genet 48: 645–648. https://doi.org/10.1136/jmedgenet-2011-100063 PMID: 21730105
16. Wang YL, Feng SH, Guo SC, Wei WJ, Li DS, et al. (2013) Confirmation of papillary thyroid cancer sus-
ceptibility loci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35 and
8p12 in a Chinese population. J Med Genet 50: 689–695. https://doi.org/10.1136/jmedgenet-2013-
101687 PMID: 23847140
17. Liyanarachchi S, Wojcicka A, Li W, Czetwertynska M, Stachlewska E, et al. (2013) Cumulative risk
impact of five genetic variants associated with papillary thyroid carcinoma. Thyroid 23: 1532–1540.
https://doi.org/10.1089/thy.2013.0102 PMID: 23659773
18. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Masson G, et al. (2012) Discovery of com-
mon variants associated with low TSH levels and thyroid cancer risk. Nat Genet 44: 319–322. https://
doi.org/10.1038/ng.1046 PMID: 22267200
19. Takahashi M, Saenko VA, Rogounovitch TI, Kawaguchi T, Drozd VM, et al. (2010) The FOXE1 locus is
a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl. Hum Mol Genet 19:
2516–2523. https://doi.org/10.1093/hmg/ddq123 PMID: 20350937
20. Jones AM, Howarth KM, Martin L, Gorman M, Mihai R, et al. (2012) Thyroid cancer susceptibility poly-
morphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus
and failure to replicate a locus on 5q24. J Med Genet 49: 158–163. https://doi.org/10.1136/jmedgenet-
2011-100586 PMID: 22282540
Genetic variants in thyroid cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0174995 April 14, 2017 11 / 13
21. Pereda CM, Lesueur F, Pertesi M, Robinot N, Lence-Anta JJ, et al. (2015) Common variants at the
9q22.33, 14q13.3 and ATM loci, and risk of differentiated thyroid cancer in the Cuban population. BMC
Genet 16: 22. https://doi.org/10.1186/s12863-015-0180-5 PMID: 25879635
22. Kohler A, Chen B, Gemignani F, Elisei R, Romei C, et al. (2013) Genome-wide association study on dif-
ferentiated thyroid cancer. J Clin Endocrinol Metab 98: E1674–1681. https://doi.org/10.1210/jc.2013-
1941 PMID: 23894154
23. Figlioli G, Kohler A, Chen B, Elisei R, Romei C, et al. (2014) Novel genome-wide association study-
based candidate loci for differentiated thyroid cancer risk. J Clin Endocrinol Metab 99: E2084–2092.
https://doi.org/10.1210/jc.2014-1734 PMID: 25029422
24. Flanagan SE, Patch AM, Ellard S (2010) Using SIFT and PolyPhen to predict loss-of-function and gain-
of-function mutations. Genet Test Mol Biomarkers 14: 533–537. https://doi.org/10.1089/gtmb.2010.
0036 PMID: 20642364
25. Ward LD, Kellis M (2012) HaploReg: a resource for exploring chromatin states, conservation, and regu-
latory motif alterations within sets of genetically linked variants. Nucleic Acids Res 40: D930–934.
https://doi.org/10.1093/nar/gkr917 PMID: 22064851
26. Li H, Deng H (2010) Systems genetics, bioinformatics and eQTL mapping. Genetica 138: 915–924.
https://doi.org/10.1007/s10709-010-9480-x PMID: 20811929
27. Cancer Genome Atlas Research N (2014) Integrated genomic characterization of papillary thyroid carci-
noma. Cell 159: 676–690. https://doi.org/10.1016/j.cell.2014.09.050 PMID: 25417114
28. Cameselle-Teijeiro J, Ruiz-Ponte C, Loidi L, Suarez-Penaranda J, Baltar J, et al. (2001) Somatic but
not germline mutation of the APC gene in a case of cribriform-morular variant of papillary thyroid carci-
noma. Am J Clin Pathol 115: 486–493. https://doi.org/10.1309/T9CC-JNMD-1WGP-YPAF PMID:
11293895
29. Zeki K, Spambalg D, Sharifi N, Gonsky R, Fagin JA (1994) Mutations of the adenomatous polyposis coli
gene in sporadic thyroid neoplasms. J Clin Endocrinol Metab 79: 1317–1321. https://doi.org/10.1210/
jcem.79.5.7962323 PMID: 7962323
30. Kumamoto K, Ishida H, Ohsawa T, Ishibashi K, Ushiama M, et al. (2015) Germline and somatic muta-
tions of the gene in papillary thyroid carcinoma associated with familial adenomatous polyposis: Analy-
sis of three cases and a review of the literature. Oncol Lett 10: 2239–2243. https://doi.org/10.3892/ol.
2015.3578 PMID: 26622826
31. Miyake N, Maeta H, Horie S, Kitamura Y, Nanba E, et al. (2001) Absence of mutations in the beta-cate-
nin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas. Pathol Int 51:
680–685. PMID: 11696170
32. Martayan A, Sanchez-Mete L, Baldelli R, Falvo E, Barnabei A, et al. (2010) Gene variants associated to
malignant thyroid disease in familial adenomatous polyposis: a novel APC germline mutation. J Endocri-
nol Invest 33: 603–606. https://doi.org/10.1007/BF03346656 PMID: 20935450
33. Theodoratou E, Campbell H, Tenesa A, McNeill G, Cetnarskyj R, et al. (2008) Modification of the asso-
ciations between lifestyle, dietary factors and colorectal cancer risk by APC variants. Carcinogenesis
29: 1774–1780. https://doi.org/10.1093/carcin/bgn082 PMID: 18375958
34. Slattery ML, Samowitz W, Ballard L, Schaffer D, Leppert M, et al. (2001) A molecular variant of the APC
gene at codon 1822: its association with diet, lifestyle, and risk of colon cancer. Cancer Res 61: 1000–
1004. PMID: 11221825
35. Guerreiro CS, Cravo ML, Brito M, Vidal PM, Fidalgo PO, et al. (2007) The D1822V APC polymorphism
interacts with fat, calcium, and fiber intakes in modulating the risk of colorectal cancer in Portuguese
persons. Am J Clin Nutr 85: 1592–1597. PMID: 17556698
36. Weinstein LS, Yu S, Warner DR, Liu J (2001) Endocrine manifestations of stimulatory G protein alpha-
subunit mutations and the role of genomic imprinting. Endocr Rev 22: 675–705. https://doi.org/10.
1210/edrv.22.5.0439 PMID: 11588148
37. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, et al. (1993) Somatic mutations in the thyrotro-
pin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365: 649–651. https://doi.org/10.
1038/365649a0 PMID: 8413627
38. Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, et al. (1990) Two G protein oncogenes in human
endocrine tumors. Science 249: 655–659. PMID: 2116665
39. Gozu HI, Bircan R, Krohn K, Muller S, Vural S, et al. (2006) Similar prevalence of somatic TSH receptor
and Gsalpha mutations in toxic thyroid nodules in geographical regions with different iodine supply in
Turkey. Eur J Endocrinol 155: 535–545. https://doi.org/10.1530/eje.1.02253 PMID: 16990652
40. Nishihara E, Amino N, Maekawa K, Yoshida H, Ito M, et al. (2009) Prevalence of TSH receptor and
Gsalpha mutations in 45 autonomously functioning thyroid nodules in Japan. Endocr J 56: 791–798.
PMID: 19550078
Genetic variants in thyroid cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0174995 April 14, 2017 12 / 13
41. Kosugi S, Hai N, Okamoto H, Sugawa H, Mori T (2000) A novel activating mutation in the thyrotropin
receptor gene in an autonomously functioning thyroid nodule developed by a Japanese patient. Eur J
Endocrinol 143: 471–477. PMID: 11022192
42. Vanvooren V, Uchino S, Duprez L, Costa MJ, Vandekerckhove J, et al. (2002) Oncogenic mutations in
the thyrotropin receptor of autonomously functioning thyroid nodules in the Japanese population. Eur J
Endocrinol 147: 287–291. PMID: 12213664
43. Dore LC, Crispino JD (2011) Transcription factor networks in erythroid cell and megakaryocyte develop-
ment. Blood 118: 231–239. https://doi.org/10.1182/blood-2011-04-285981 PMID: 21622645
44. Hu G, Schones DE, Cui K, Ybarra R, Northrup D, et al. (2011) Regulation of nucleosome landscape and
transcription factor targeting at tissue-specific enhancers by BRG1. Genome Res 21: 1650–1658.
https://doi.org/10.1101/gr.121145.111 PMID: 21795385
Genetic variants in thyroid cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0174995 April 14, 2017 13 / 13
